Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telavancin - Cumberland Pharmaceuticals

Next Previous
Drug Profile

Telavancin - Cumberland Pharmaceuticals

Alternative Names: Arbelic; TD-6424; Telavancin hydrochloride; Vibativ

Latest Information Update: 21 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theravance; Theravance Biopharma
  • Developer Clinigen; Cumberland Pharmaceuticals; Innoviva; MEGAPharma; PENDOPHARM; SciClone Pharmaceuticals; Theravance Biopharma; University of Illinois at Chicago
  • Class Aminoglycosides; Anti-infectives; Antibacterials; Glycopeptides; Lipopeptides; Peptide antibiotics
  • Mechanism of Action Cell membrane permeability enhancers; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Skin and soft tissue infections

Highest Development Phases

  • Marketed Bacteraemia; Nosocomial pneumonia; Skin and soft tissue infections; Ventilator associated pneumonia
  • Preregistration Bacterial infections
  • Phase III Osteomyelitis
  • No development reported Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 31 Dec 2023 Cumberland Pharmaceuticals has patent protection in USA related to telavancin composition of matter and methods before December 2023
  • 10 Oct 2023 Clinical trials in Bacterial infections (In children) in USA (IV), prior to October 2023
  • 10 Oct 2023 PK and adverse events data from a clinical trial in Bacterial infections released by Cumberland Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top